Literature DB >> 26954372

Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir-DF-associated renal tubulopathy.

James M Mikula1, Maura M Manion2, Frank Maldarelli3, Lucila M Suarez2, Jaha F Norman-Wheeler4, Alex G Ober2, Robin L Dewar5, Jeffrey B Kopp6, H Clifford Lane2, Alice K Pau2.   

Abstract

We describe a patient with two recent episodes of tenofovir disoproxil fumarate (TDF)-associated acute kidney injury and six-class drug-resistant HIV infection who achieved and maintained viral suppression without worsening kidney function on a regimen including tenofovir alafenamide (TAF) through 48 weeks of therapy. The safety and efficacy of TAF in patients with TDF-associated renal tubulopathy and multiple drug resistant HIV has not yet been described. TAF may represent a useful option to maximally suppress HIV in patients with these complications.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26954372      PMCID： PMC5016206          DOI： 10.3851/IMP3040

Source DB:  PubMed          Journal:  Antivir Ther        ISSN： 1359-6535


  20 in total

1.  Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.

Authors:  Martin Markowitz; Andrew Zolopa; Kathleen Squires; Peter Ruane; Dion Coakley; Brian Kearney; Lijie Zhong; Michael Wulfsohn; Michael D Miller; William A Lee
Journal:  J Antimicrob Chemother       Date:  2014-02-06       Impact factor: 5.790

2.  Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.

Authors:  Nicolas A Margot; Audun Johnson; Michael D Miller; Christian Callebaut
Journal:  Antimicrob Agents Chemother       Date:  2015-07-06       Impact factor: 5.191

3.  Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.

Authors:  Anthony Mills; Gordon Crofoot; Cheryl McDonald; Peter Shalit; Jason A Flamm; Joseph Gathe; Anita Scribner; David Shamblaw; Michael Saag; Huyen Cao; Hal Martin; Moupali Das; Anne Thomas; Hui C Liu; Mingjin Yan; Christian Callebaut; Joseph Custodio; Andrew Cheng; Scott McCallister
Journal:  J Acquir Immune Defic Syndr       Date:  2015-08-01       Impact factor: 3.731

4.  Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.

Authors:  Slim Fourati; Charlotte Charpentier; Corinne Amiel; Laurence Morand-Joubert; Sandrine Reigadas; Mary-Anne Trabaud; Constance Delaugerre; Florence Nicot; Audrey Rodallec; Anne Maillard; Audrey Mirand; Hélène Jeulin; Brigitte Montès; Francis Barin; Dominique Bettinger; Hélène Le Guillou-Guillemette; Sophie Vallet; Anne Signori-Schmuck; Diane Descamps; Vincent Calvez; Philippe Flandre; Anne-Genevieve Marcelin
Journal:  J Antimicrob Chemother       Date:  2015-01-03       Impact factor: 5.790

5.  Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.

Authors:  Christine Katlama; Roberto Esposito; Jose M Gatell; Jean-Christophe Goffard; Beatriz Grinsztejn; Anton Pozniak; Jurgen Rockstroh; Albrecht Stoehr; Norbert Vetter; Patrick Yeni; Wim Parys; Tony Vangeneugden
Journal:  AIDS       Date:  2007-02-19       Impact factor: 4.177

Review 6.  Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.

Authors:  Andrew M Hall; Bruce M Hendry; Dorothea Nitsch; John O Connolly
Journal:  Am J Kidney Dis       Date:  2011-03-23       Impact factor: 8.860

Review 7.  Darunavir: a review of its use in the management of HIV-1 infection.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2014-01       Impact factor: 11.431

8.  Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study.

Authors:  Antonella Castagna; Franco Maggiolo; Giovanni Penco; David Wright; Anthony Mills; Robert Grossberg; Jean-Michel Molina; Julie Chas; Jacques Durant; Santiago Moreno; Manuela Doroana; Mounir Ait-Khaled; Jenny Huang; Sherene Min; Ivy Song; Cindy Vavro; Garrett Nichols; Jane M Yeo
Journal:  J Infect Dis       Date:  2014-01-19       Impact factor: 5.226

9.  The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound.

Authors:  Mark Wainberg; Kaitlin Anstett; Thibault Mesplede; Peter Quashie; Yingshan Han; Maureen Oliveira
Journal:  J Int AIDS Soc       Date:  2014-11-02       Impact factor: 5.396

10.  Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.

Authors:  Anthony Mills; Jose R Arribas; Jaime Andrade-Villanueva; Giovanni DiPerri; Jan Van Lunzen; Ellen Koenig; Richard Elion; Matthias Cavassini; Jose Valdez Madruga; Jason Brunetta; David Shamblaw; Edwin DeJesus; Chloe Orkin; David A Wohl; Indira Brar; Jeffrey L Stephens; Pierre-Marie Girard; Gregory Huhn; Andrew Plummer; Ya-Pei Liu; Andrew K Cheng; Scott McCallister
Journal:  Lancet Infect Dis       Date:  2015-11-02       Impact factor: 25.071
View more
  2 in total

1.  Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient.

Authors:  Maile Young Karris
Journal:  AIDS Res Hum Retroviruses       Date:  2017-05-12       Impact factor: 2.205

2.  Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service.

Authors:  Dane Turner; Douglas Drak; Catherine C O'Connor; David J Templeton; David M Gracey
Journal:  AIDS Res Ther       Date:  2019-12-07       Impact factor: 2.250
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.